CU20200069A7 - CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y LAS COMPOSICIONES VACUNALES QUE LOS CONTIENEN - Google Patents

CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y LAS COMPOSICIONES VACUNALES QUE LOS CONTIENEN

Info

Publication number
CU20200069A7
CU20200069A7 CU2020000069A CU20200069A CU20200069A7 CU 20200069 A7 CU20200069 A7 CU 20200069A7 CU 2020000069 A CU2020000069 A CU 2020000069A CU 20200069 A CU20200069 A CU 20200069A CU 20200069 A7 CU20200069 A7 CU 20200069A7
Authority
CU
Cuba
Prior art keywords
cov
sars
vaccine compositions
binding domain
carrier protein
Prior art date
Application number
CU2020000069A
Other languages
English (en)
Other versions
CU24689B1 (es
Inventor
Ayo Tammy Boggiano
Castillo Sonsire Fernández
Ricardo Manuel García
Rivera Dagmar García
Rivera Daniel García
Magraz Eduardo Ojito
Hernández Reynaldo Oliva
González Ubel Jesús Ramírez
Noda Laura Marta Rodríguez
Ramírez Belinda Sánchez
Mederos Darielys Santana
Balbín Yury Valdés
Bencomo Vicente Guillermo Verez
Original Assignee
Ct Inmunologia Molecular
Inst Finlay De Vacunas
Univ La Habana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular, Inst Finlay De Vacunas, Univ La Habana filed Critical Ct Inmunologia Molecular
Priority to CU2020000069A priority Critical patent/CU24689B1/es
Priority to KR1020237015371A priority patent/KR20230129223A/ko
Priority to PCT/CU2021/050009 priority patent/WO2022073528A1/es
Priority to JP2023521032A priority patent/JP2023547045A/ja
Priority to CA3198217A priority patent/CA3198217A1/en
Priority to BR112023006340A priority patent/BR112023006340A2/pt
Priority to US18/029,766 priority patent/US20230381295A1/en
Priority to CN202180081320.2A priority patent/CN117177774A/zh
Priority to AU2021355767A priority patent/AU2021355767A1/en
Priority to EP21820101.0A priority patent/EP4226947A1/en
Publication of CU20200069A7 publication Critical patent/CU20200069A7/es
Priority to CL2023000985A priority patent/CL2023000985A1/es
Publication of CU24689B1 publication Critical patent/CU24689B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención se relaciona con la biotecnología, específicamente con el campo de la salud humana. Describe conjugados covalentes del dominio de unión al receptor del virus SARS-CoV-2 con una proteína portadora, el método para obtener esos conjugados y las composiciones vacunales que los contienen. Las composiciones vacunales que se describen en la presente invención son útiles en la prevención de la infección por el virus SARS-CoV-2 ya que inducen una potente respuesta de anticuerpos neutralizantes.</p>
CU2020000069A 2020-10-05 2020-10-05 CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN CU24689B1 (es)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CU2020000069A CU24689B1 (es) 2020-10-05 2020-10-05 CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN
BR112023006340A BR112023006340A2 (pt) 2020-10-05 2021-10-05 Conjugado covalente, composição de vacina, procedimento para a preparação do conjugado covalente, e, uso da composição de vacina
PCT/CU2021/050009 WO2022073528A1 (es) 2020-10-05 2021-10-05 Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2 y una proteína portadora y las composiciones vacunales que los contienen
JP2023521032A JP2023547045A (ja) 2020-10-05 2021-10-05 Ｓａｒｓ－ｃｏｖ－２受容体結合ドメインと担体タンパク質との共有結合コンジュゲート並びにそれらを含有するワクチン組成物
CA3198217A CA3198217A1 (en) 2020-10-05 2021-10-05 Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them
KR1020237015371A KR20230129223A (ko) 2020-10-05 2021-10-05 Sars-cov-2 수용체 결합 도메인과 담체 단백질의 공유결합체 및 그것을 함유하는 백신 조성물
US18/029,766 US20230381295A1 (en) 2020-10-05 2021-10-05 Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them
CN202180081320.2A CN117177774A (zh) 2020-10-05 2021-10-05 Sars-cov-2受体结合结构域与载体蛋白的共价缀合物以及包含它们的疫苗组合物
AU2021355767A AU2021355767A1 (en) 2020-10-05 2021-10-05 Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them
EP21820101.0A EP4226947A1 (en) 2020-10-05 2021-10-05 Covalent conjugates of the sars-cov-2 receptor-binding domain and a carrier protein and vaccine compositions that contain them
CL2023000985A CL2023000985A1 (es) 2020-10-05 2023-04-05 Conjugados covalentes del dominio de unión al receptor del virus sars-cov-2; proteína portadora; composiciones vacunales

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000069A CU24689B1 (es) 2020-10-05 2020-10-05 CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN

Publications (2)

Publication Number Publication Date
CU20200069A7 true CU20200069A7 (es) 2022-05-11
CU24689B1 CU24689B1 (es) 2023-12-07

Family

ID=78822472

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000069A CU24689B1 (es) 2020-10-05 2020-10-05 CONJUGADOS COVALENTES DEL DOMINIO DE UNIÓN AL RECEPTOR DEL VIRUS SARS-CoV-2 Y UNA PROTEÍNA PORTADORA Y PROCEDIMIENTO DE OBTENCIÓN

Country Status (11)

Country Link
US (1) US20230381295A1 (es)
EP (1) EP4226947A1 (es)
JP (1) JP2023547045A (es)
KR (1) KR20230129223A (es)
CN (1) CN117177774A (es)
AU (1) AU2021355767A1 (es)
BR (1) BR112023006340A2 (es)
CA (1) CA3198217A1 (es)
CL (1) CL2023000985A1 (es)
CU (1) CU24689B1 (es)
WO (1) WO2022073528A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111606981B (zh) * 2020-05-27 2022-02-08 中国医学科学院基础医学研究所 Sars-cov冠状病毒s1蛋白多肽及其应用

Also Published As

Publication number Publication date
CA3198217A1 (en) 2022-04-14
CU24689B1 (es) 2023-12-07
JP2023547045A (ja) 2023-11-09
US20230381295A1 (en) 2023-11-30
WO2022073528A1 (es) 2022-04-14
EP4226947A1 (en) 2023-08-16
CN117177774A (zh) 2023-12-05
BR112023006340A2 (pt) 2023-05-09
AU2021355767A1 (en) 2023-06-01
CL2023000985A1 (es) 2023-12-01
KR20230129223A (ko) 2023-09-07

Similar Documents

Publication Publication Date Title
CY1123534T1 (el) Αντισωματα που περιλαμβανουν τροποποιημενες βαριες σταθερες περιοχες
PE20211696A1 (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
CY1124982T1 (el) Εμβολιο mycoplasma hyopneumoniae
CY1121998T1 (el) Συνδυασμενο εμβολιο pcv/mycoplasma hyopneumoniae
CL2018000703A1 (es) Anticuerpos anti-pdgfr-beta y usos de los mismos (divisional de sol. n°1924-15)
CY1121389T1 (el) Αντισωματα που δεσμευονται ειδικα με την α-τοξινη toy staphylococcus aureus και μεθοδοι χρησης
BR112018014986A2 (pt) composição farmacêutica compreendendo construtos de anticorpo biespecífico
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
AR077756A1 (es) Anticuerpos especificos para bacterias gram-positivas
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CY1121673T1 (el) Εξουδετερωση αντισωματων στις κυριες εξωτοξινες tcda και tcdb της λοιμωξης clostridium difficile
GT201700034A (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
BR112016027912A2 (pt) molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer
ECSP11011538A (es) Anticuerpo anti-axl
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
BR112017003236A2 (pt) anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
EA202092202A1 (ru) Конструкции антител к ror
ES2721882T3 (es) Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
AR110920A1 (es) Conjugados de fármaco anticuerpo anti-ccr7
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
CO6640284A2 (es) Miembros enlazadores para citomegalovirus humano